FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer.
Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting.

Key topics include:
• Overview of biliary tract cancer and its treatment landscape
• Study design and patient characteristics from the HERIZON-BTC-01 trial
• Key findings, including overall response rates and duration of response
• The importance of HER2 testing and its implications for treatment sequencing
• Side effect profiles and management strategies for Zanidatamab
• Future directions and ongoing clinical trials

Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer.
Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com